LivaNova PLC (LIVN)
NASDAQ: LIVN · Real-Time Price · USD
67.66
-0.76 (-1.11%)
Feb 23, 2026, 1:33 PM EST - Market open
LivaNova Revenue
LivaNova had revenue of $357.75M in the quarter ending September 30, 2025, with 12.46% growth. This brings the company's revenue in the last twelve months to $1.35B, up 8.63% year-over-year. In the year 2024, LivaNova had annual revenue of $1.25B with 8.66% growth.
Revenue (ttm)
$1.35B
Revenue Growth
+8.63%
P/S Ratio
2.71
Revenue / Employee
$465,159
Employees
2,900
Market Cap
3.69B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.25B | 99.89M | 8.66% |
| Dec 31, 2023 | 1.15B | 131.74M | 12.89% |
| Dec 31, 2022 | 1.02B | -13.56M | -1.31% |
| Dec 31, 2021 | 1.04B | 101.12M | 10.82% |
| Dec 31, 2020 | 934.24M | -149.93M | -13.83% |
| Dec 31, 2019 | 1.08B | -22.79M | -2.06% |
| Dec 31, 2018 | 1.11B | 94.68M | 9.35% |
| Dec 31, 2017 | 1.01B | 47.42M | 4.91% |
| Dec 31, 2016 | 964.86M | 601.62M | 165.63% |
| Dec 31, 2015 | 363.24M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bruker | 3.44B |
| Bio-Rad Laboratories | 2.58B |
| Bio-Rad Laboratories | 2.58B |
| Integer Holdings | 1.85B |
| Haemonetics | 1.32B |
| iRhythm Holdings | 747.14M |
| Alphatec Holdings | 728.02M |
| TransMedics Group | 566.35M |
LIVN News
- 4 weeks ago - LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results - Business Wire
- 5 weeks ago - LivaNova PLC (LIVN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - LivaNova to Present at J.P. Morgan Healthcare Conference in January - Business Wire
- 2 months ago - LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting - Business Wire
- 2 months ago - LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea - Business Wire
- 3 months ago - LivaNova to Present at Piper Sandler Healthcare Conference in December - Business Wire
- 3 months ago - LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services - Business Wire
- 3 months ago - LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day - Business Wire